UNSPSC 51391728: Metiprenaline

This classification denotes a beta-adrenergic agonist with the molecular formula C12H19NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1WBF92D66N, chemically known as vanillyl alcohol, alpha-((isopropylamino)methyl)- but generally known as metiprenaline, which bears US NIH Compound Identifier 68951. European Medicines Agency schedules Metiprenaline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08893MIG.

UNSPSC 51391728 Metiprenaline is a Commodity code that in recent state and local procurement activity covers the purchase of naloxone and related pharmaceutical products for public health and community health initiatives. The recent opportunities show that state and local governments are buying naloxone in bulk quantities for harm reduction and overdose response, alongside complementary drug deactivation and pharmacy management services. Issuing bodies include county health departments and state health and human services agencies. Seminole County, Florida has solicited naloxone and safe drug deactivation systems through competitive bidding, while the Texas Health and Human Services Commission has issued a Request for Information to explore direct-to-manufacturer prescription fulfillment models that could reshape how state agencies source pharmaceuticals and manage pharmacy benefit programs.

Activity under the code centers on Florida and Texas, with Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (response deadline July 26, 2023, through the county e-Procurement Portal) and the Texas HHS Commission's RFI HHS0017013 seeking vendor capabilities for direct-to-manufacturer prescription programs (response deadline April 3, 2026). The Seminole County procurement requires quarterly deliveries to the Seminole County Community Health Building in Sanford, carries a two-year initial term with one-year renewal option, and mandates E-Verify compliance and drug-free workplace certification. The Texas RFI represents preliminary market intelligence gathering ahead of a formal RFP and seeks vendor experience with direct contracting for self-insured employers and state agencies, negotiated net pricing models, and value-based or outcomes-based agreements. Neither opportunity specifies explicit set-aside or disadvantaged-enterprise designations.